Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights


Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025

Read the rest here:
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

Related Posts